Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.
 

Corporate Investor Presentation

Rigel Corporate Investor Presentation

More »
Recent News
DateTitle 
01/23/19
- Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey - Rigel to receive an upfront payment of $30 million, with the potential for $297.5 million in total regulatory and commercial milestones - Potential milestones to Rigel include a $20 million payment
01/07/19
Reports 1,794 total bottles of TAVALISSE™ (fostamatinib disodium hexahydrate) sold in 2018 SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc.  (Nasdaq: RIGL) today provided a business update, including the quantity of TAVALISSE™ bottles sold in 2018 and its cash
01/03/19
SOUTH SAN FRANCISCO , Jan. 3, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and CEO, is scheduled to present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at

Stock Quote

(Common Stock)
Exchange (US Dollar)
Price
Change (%)
Volume
Data as of
More »
Upcoming Events
More events are coming soon.
What's New

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site